Everlab raises $65 million to connect preventive care

Everlab raised $65 million in Series A funding as the Melbourne startup tries to turn preventive care into a connected clinical service.

Airtree Ventures led the round. Plural, Left Lane Capital, b2venture and Australian Test cricket captain Pat Cummins joined the investment. Everlab raised $15 million in seed funding less than a year ago.

Everlab founders Marc Hermann, Anshul Jain, Dr Steven Lu and Sam Kothari started the company in 2023. The company now says it serves more than 20,000 patients across Australia and New Zealand, works with more than 180 clinicians and connects with more than 1,850 healthcare provider locations.

Everlab’s claim centers on a familiar failure in primary care. Patients see general practitioners, specialists, pathology labs and imaging providers, then carry the burden of joining the pieces. Medical records sit in separate systems. Wearable data stays in consumer apps. Follow-up plans often depend on the patient’s memory and calendar.

Everlab says its app gives patients and clinicians one view of test results, medical records, wearable data, prescriptions and care plans. The company also says it processes more than 200,000 health reports each month and has handled more than 21 million biomarker test results.

The technical pitch depends on data integration more than model novelty. Everlab says it uses AI to analyze health information and support care planning, but the company has not named model architectures, training data sources or benchmark results. That matters because health AI claims need more than volume metrics. Clinicians and patients need to know error rates, escalation rules, bias testing and audit trails.

Hermann told SmartCompany that preventive health has remained service-heavy, which keeps it out of reach for many patients. Everlab wants software to reduce clinician workload by organizing records, supporting asynchronous communication and coordinating care across providers.

The useful part sits in workflow design. If a clinician can see blood work, specialist notes, wearable trends and past advice in one place, that clinician can spend less time chasing context. If the system tracks follow-up steps after a risk marker appears, the patient has a better chance of acting before a condition worsens.

Everlab says more than 25% of members received findings that the usual healthcare system had not identified. Hermann also said the company sees a polyp detection rate above 50% among members referred for colonoscopy. Those claims need clinical context: patient selection, referral criteria and comparison groups can change detection rates.

The company’s next test will come in the UK. Everlab plans to use the new funding to strengthen clinical and technology infrastructure and support international expansion. The UK market brings demand for faster access to care, but it also brings a strict regulatory environment, integration barriers and a public health system with its own data rules.

Investors see a large market in preventive health, but Everlab still needs to prove that its model improves outcomes at scale. Better cholesterol, inflammation, fitness and muscle mass markers would help. So would published clinical validation, transparent AI evaluation and evidence that patients outside high-income groups can afford and use the service.

For now, Everlab has capital, usage numbers and a clear product thesis. The hard part comes next: turning scattered health data into care that clinicians trust and patients follow.